ClinicalTrials.gg
RecruitingNCT05304377CMLUpdated Apr 1, 2026

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

A Phase 1 interventional study of ELVN-001 in Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive and Cml, sponsored by Enliven Therapeutics. Recruiting at 45 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Enliven Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany — 10 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany.

Planned enrollment
29th of 77
250 · median 171
Started
2022
with 2 others
Phase 1
8 of 90
1 open now
Primary completion
2027-12
later than 7 of 15 live
Registered
81st of 90
by date

Among the 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany, this one is the 29th largest by planned enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2022, is one of 8 in phase 1, reaches primary completion later than 7 of the 15 other live ones, and was the 81st registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

10 of the 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.

Read the detailed description

This first-in-human trial with ELVN-001 is a dose escalation study with the primary purpose to identify the recommended dose(s) for expansion (RDEs) of single agent ELVN-001 in chronic phase CML with or without T315I mutations. The safety, tolerability and pharmacokinetic profile of ELVN-001 will be assessed together with an evaluation of changes in BCR-ABL1 transcript. An understanding of the safety profile, PK and preliminary evidence of anti-CML activity will be used to inform future development of ELVN-001 in adults with CML. By virtue of its predicted pharmacological profile ELVN-001 has the potential to be tolerable and achieve a deep molecular response in patients with CML with or without T315I mutations who do not tolerate or benefit from available TKIs.

03

Conditions studied

  • Chronic Myeloid Leukemia
  • Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Cml

Keywords

  • CML
  • Tyrosine kinase inhibitor
  • T315I
  • T315I mutant
  • BCR-ABL
  • ENABLE
  • active site inhibitor of BCR-ABL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BCR-ABL1 positive CML in chronic phase, with or without T315I mutation.
  • US: The patient has failed or is intolerant to at least one prior second-generation tyrosine kinase inhibitor (TKI) or asciminib. Rest of World: The patient has failed, is intolerant to, or not a candidate for, available therapies known to be active for treatment of their CML (country-specific criteria may vary).
  • performance status of 0 to 2.
  • Adequate hematologic, hepatic and renal function.
  • Prior bone marrow transplant allowed if ≥ 6 months prior to the first dose of ELVN-001.

Exclusion criteria

Exclusion Criteria:

  • Treatment with anti-cancer or anti-CML therapy within 7 days or 5 half-lives, whichever is longer.
  • History of acute tyrosine kinase inhibitor (TKI)-related pancreatitis within 6 months of study entry. Active chronic pancreatitis, or pancreatic disease due to any cause.
  • >470 ms.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Phase 1a Dose Escalation

    ELVN-001 administered in 3+3 dose escalation

    Drug: ELVN-001

  • Experimental
    Phase 1b Dose Expansion (non-T315I)

    ELVN-001 administered at one or more recommended dose(s) for expansion in CML without T315I mutations

    Drug: ELVN-001

  • Experimental
    Phase 1b expansion (T315I)

    ELVN-001 administered at the recommended dose for expansion for CML with T315I mutation

    Drug: ELVN-001

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1a: Incidence of dose limiting toxicities

    DLTs will be used to support that the recommended doses for expansion are \</= MTD

    Time frame: 28 days

  2. Phase 1a: Incidence of adverse events (AEs)

    Adverse events will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: up to 28 days

  3. Phase 1a: Incidence of clinically significant laboratory abnormalities

    Clinically significant laboratory abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: up to 28 days

  4. Phase 1a: Incidence of clinically significant ECG abnormalities

    Clinically significant ECG abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: up to 28 days

  5. Phase 1b: Incidence of adverse events

    Adverse events will be used to support that the dose(s) evaluated in expansion is tolerable

    Time frame: up to 3 years

  6. Phase 1b: Incidence of clinically significant laboratory abnormalities

    Clinically significant ECG abnormalities will be used to support that the dose(s) evaluated in expansion is tolerable

    Time frame: up to 3 years

  7. Phase 1b: Incidence of clinically significant ECG abnormalities

    Clinically significant ECG abnormalities will be used to support that the recommended dose(s) evaluated in expansion is tolerable

    Time frame: up to 3 years

Secondary outcomes

  1. Phase 1a and 1b: area under the curve

    PK parameter based on measurement of drug concentration in blood over time

    Time frame: 6 months

  2. Phase 1a and 1b: maximum concentration

    PK parameter based on measurement of drug concentration in blood

    Time frame: 6 months

  3. Phase 1a and 1b: time of maximum concentration

    PK parameter which is the time at which the highest concentration of drug in the blood is measured

    Time frame: 6 months

  4. Phase 1a and 1b: minimum concentration

    PK parameter based on the measurement of the drug concentration that is at the lowest level once steady state has been achieved.

    Time frame: 6 months

  5. Phase 1a and 1b: Molecular response (MR)

    measured by quantitative polymerase chain reaction of BCR-ABL transcript levels

    Time frame: up to 3 years

  6. Phase 1b: Duration of Molecular Response

    Time from first molecular response (as measured by quantitative polymerase chain reaction of BCR-ABL transcript levels) to loss of response or discontinuation of study drug

    Time frame: up to 3 years

  7. Phase 1b: Complete Hematologic Response (CHR)

    The proportion of patients who achieve a CHR who are not in CHR at baseline

    Time frame: up to 3 years

07

Study locations

38 of 45 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Michael Mauro, MD · Contact+1 347 798 9213
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
    Recruiting
    • David Levitz MD · Contact718-920-4321
  • Oregon Health & Science University-Knight Cardiovascular Institute
    Portland, Oregon 97239, United States
    Recruiting
    • Michael Heinrich, MD · Contact(503) 418-1964
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Fadi Haddad, MD · Contact877-632-6789
  • Royal Adelaide Hospital
    Adelaide, SA 5000, Australia
    Recruiting
    • Naranie Shanmuganathan, Dr · Contact+61 8 7074 0000
  • UZ Gent
    Ghent, 9000, Belgium
    Recruiting
    • Dominiek Mazure, Dr. · Contact+32 9 332 21 11
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Peter Vandenberghe, Dr. · Contact+32 16 33 22 11
  • CHU Liege
    Liège, 4000, Belgium
    Recruiting
    • Marie Lejeune, Dr. · Contact+32 4 323 00 00
  • University Health Network (UHN) - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Dong Hwan Dennis Kim, Dr · Contact+1 416 946 4501
  • CHU Amiens Picardie Site Sud
    Amiens, 80054, France
    Recruiting
    • Amandine Charbonnier, Dr · Contact+33 322455914
  • Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
    Bordeaux, 33076, France
    Recruiting
    • Gabriel Etienne, Dr · Contact+33 5 56 33 33 33
  • CHRU de Lille - Hopital Calmette-Boulevard du Pr Leclercq CHRU Lille
    Lille, 59000, France
    Recruiting
    • Valerie Coiteux, Dr · Contact+33 3 20 44 59 62
  • Centre Hospitalier Universitaire (CHU) De Limoges Hopital Dupuytren
    Limoges, 87000, France
    Recruiting
    • Pascal Turlure, Dr · Contact+33 5 55 05 55 55
  • Centre Leon Berard
    Lyon, 69008, France
    Recruiting
    • Franck Nicolini, Dr · Contact+33 478782737
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Uniklinik RWTH Aachen Medizinische
    Aachen, 52074, Germany
    Recruiting
    • Martina Crysandt, Dr · Contact+49 241 8080862
  • Charite Campus Virchow
    Berlin, 13353, Germany
    Recruiting
    • Philipp Le Coutre, Dr · Contact+49 30 450 665 307
  • Klinikum der Goethe Universitat
    Frankfurt, 60596, Germany
    Recruiting
    • Fabian Lang, Dr · Contact+49 821 4861274
  • Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes
    Homburg, 66421, Germany
    Recruiting
    • Sarah Altmeyer, Dr · Contact+49 68411615001
  • Universitaetsklinikum Jena
    Jena, 07747, Germany
    Recruiting
    • Andreas Hochhaus, Prof Dr · Contact+49 3641 934200
  • Medizinische Universitatsklinik Mannheim der Universitat Heidelberg
    Mannheim, 68167, Germany
    Recruiting
    • Susanne Saussele, Prof Dr · Contact+49 621 383 6966
  • Universitaetsmedizin Rostock
    Rostock, 18057, Germany
    Recruiting
    • Christian Junghanss, Dr · Contact+49 3814947421
  • Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika
    Budapest, 1083, Hungary
    Recruiting
    • Istvan Tackas MD · Contact+36 1 459 1500
  • Pecsi Tudomanyegyetem Klinikai Kozpont (University of Pecs, Clinical Centre)
    Pécs, 7624, Hungary
    Recruiting
    • Hussain Alizadeh, Dr · Contact+36 72 501 500
  • Hadassah Medical Center
    Jerusalem, 9112001, Israel
    Recruiting
    • David Lavie, Dr. · Contact+972 02-6779267
  • The Galilee Medical Center
    Nahariya, 2210001, Israel
    Recruiting
    • Galia Stemer, Dr. · Contact+972 04-9107301
  • Rabin Medical Center
    Petah Tikva, 4941492, Israel
    Recruiting
    • Adi Shacham-Abulafia, Dr. · Contact+972 03-9377909
  • Azienda Ospedaliero Universitaria Delle Marche
    Ancona, 60126, Italy
    Recruiting
    • Erika Morsia, Dr. · Contact+39 071 5961
  • Radboud University Medical Center
    Nijmegen, 6525, Netherlands
    Recruiting
    • N.M.A. Blijlevens, Dr. · Contact+31 (0)24 361 11 11
  • Szpital Specjalistycnzy im. Jedrzeja Sniadeckiego w Nowym Saczu
    Nowy Sącz, 33-300, Poland
    Recruiting
    • Szymon Fornagiel, Dr · Contact+48 18 443 88 77
  • MICS Centrum Medyczne Torun
    Torun, 87-100, Poland
    Recruiting
    • Dominik Chraniuk, Dr. · Contact+48 662 062 410
  • Instytut Hematologii I Transfuzjologii
    Warsaw, 02-776, Poland
    Recruiting
    • Ewa Lech-Maranda, Dr. · Contact+48 22 349 61 00
  • Chonbuk National University Hospital
    Jeonju, Jeollabuk-do 54907, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Keimyung University Dongsan Hospital
    Daegu, 42601, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Uijeongbu Eulji Medical Center
    Gyeonggi-do, 11749, South Korea
    Recruiting
    • Dong-Wook Kim, Dr · Contact+82 3118990001
  • Chonnam National University Hwasun Hospital
    Hwasun, 58128, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Samsung Medical Center
    Seoul, 06351, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Del Mar
    Barcelona, 08003, Spain
    Recruiting
    • Patricia Velez Tenza, Dr · Contact+34 932 48 30 00
  • Hospital Universitario de Gran Canaria Dr. Negrin, Servicio Canario e Salud (SCS)
    Las Palmas de Gran Canaria, 35010, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
    • Maria Raquel de Paz Arias, Dr · Contact+34 917 27 70 00
  • Complejo Hospitalario de Toledo - Hospital Virgen de la Salud
    Toledo, 45007, Spain
    Terminated

    Not enrolling at this site — choose another above.

  • Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
    Valencia, 46026, Spain
    Recruiting
    • Elvira Mora Castera, Dr · Contact+34 961 24 40 00
  • Beatson West of Scotland Cancer Centre, Gartnavel General Hospital
    Glasgow, G12 0YN, United Kingdom
    Recruiting
    • Mhairi Copland, Dr · Contact+44 141 301 7000
  • Hammersmith Hospital Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
    Recruiting
    • Dragana Milojkovic, Dr. · Contact+44 20 3313 8335
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
    Recruiting
    • John Chadwick, Dr · Contact+44 (0) 161 446 3000
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Mar 31, 2022
StartActual
May 22, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05304377
Lead sponsor
Enliven Therapeutics
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
May 22, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Study Contact
Contact
ELVN-001-101@enliventherapeutics.com
707-799-3272

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relcobatinib

Start the discussion